The drug had to be injected twice a day, which had to be done within 15-30 minutes before breakfast and dinner
This work was supported by the National Institutes of Health under award numbers 2R01HL115189, P30DK04056, UE5DK137285, and U24 DK132733, and by the National Clinician Scholars Program at the Duke Clinical and Translational Science Institute
This broadening application reflects a growing understanding of GLP-1s diverse physiological effects beyond traditional weight management
The timing depends on the FDA's rigorous review process of the clinical trial data on retatrutide once it is submitted, however, it is unlikely to be approved and available until at least late 2026 and possibly into 2027 or 2028
Risk of bias in the included studies Supplemental Fig
What matters is consistency